Literature DB >> 27639088

Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.

Salvatore Petta1, Vincent Wai-Sun Wong2,3, Calogero Cammà1, Jean-Baptiste Hiriart4, Grace Lai-Hung Wong2,3, Fabio Marra5, Julien Vergniol4, Anthony Wing-Hung Chan6, Vito Di Marco1, Wassil Merrouche4, Henry Lik-Yuen Chan2,3, Marco Barbara1, Brigitte Le-Bail7,8, Umberto Arena5, Antonio Craxì1, Victor de Ledinghen4,7.   

Abstract

Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132-298, middle 299-338, higher 339-400 dB/m). Among patients with F0-F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3-F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848-0.982; 0.830, 0.753-0.908; 0.806, 0.723-0.890). As a consequence, in subjects with F0-F2 fibrosis, the rates of false-positive LSM results for F3-F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values.
CONCLUSIONS: In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145-1155).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 27639088     DOI: 10.1002/hep.28843

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  52 in total

1.  Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis.

Authors:  Razan M Bader; Maureen M Jonas; Paul D Mitchell; Shanna Wiggins; Christine K Lee
Journal:  J Cyst Fibros       Date:  2018-12-01       Impact factor: 5.482

2.  Risk Assessment of Hepatocellular Carcinoma in General Population by Liver Stiffness in Combination with Controlled Attenuation Parameter using Transient Elastography: A Cross Sectional Study.

Authors:  Takaaki Sugihara; Masahiko Koda; Tomomitsu Matono; Kinya Okamoto; Yoshikazu Murawaki; Hajime Isomoto; Shiho Tokunaga
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

Review 3.  Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions.

Authors:  Rohit Loomba
Journal:  J Hepatol       Date:  2017-12-02       Impact factor: 25.083

Review 4.  Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ma Ai Thanda Han; Rola Saouaf; Walid Ayoub; Tsuyoshi Todo; Edward Mena; Mazen Noureddin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-03-09       Impact factor: 5.045

5.  Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance?

Authors:  Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2017-07-04

6.  A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease.

Authors:  Heather Mary-Kathleen Kosick; Aline Keyrouz; Oyedele Adeyi; Giada Sebastiani; Keyur Patel
Journal:  Dig Dis Sci       Date:  2021-01-03       Impact factor: 3.199

Review 7.  Invasive and non-invasive assessment of portal hypertension.

Authors:  Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; James Pang; Jeremy Lok Wei; Vincent Wai-Sun Wong
Journal:  Hepatol Int       Date:  2017-03-30       Impact factor: 6.047

Review 8.  Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.

Authors:  Elliot B Tapper; Rohit Loomba
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-02-21       Impact factor: 46.802

9.  Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.

Authors:  Hye Won Lee; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang Joon Kim; Kwang-Hyub Han
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

Review 10.  The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature.

Authors:  Max M Puthenpura; Vishal Patel; John Fam; Leon Katz; David S Tichansky; Stephan Myers
Journal:  Obes Surg       Date:  2020-09-26       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.